CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 112 enrolled
Drug / intervention
OTL38 for Injection +1 moredrug
Likely dose
OTL38 for Injection 3 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04241315
NCT04241315Phase 3Completed

A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

On Target Laboratories, LLC·interventional·Posted Jan 27, 2020·Updated Mar 23, 2023

In Brief

A Phase 3 clinical trial evaluating OTL38 for Injection and Near infrared camera imaging system for Lung Neoplasms and Lung Cancer. Completed, enrolled 112 participants across 12 sites.

Detailed Summary

This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsClinipace Worldwide

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 27, 2020
Enrollment StartMar 26, 2020
Primary CompletionOct 7, 2021
Study CompletionNov 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.4 years ago

Interventions

OTL38 for Injectiondrug

Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

Near infrared camera imaging systemdevice

Near infrared camera imaging system